GlassScriptPhysician profile
Eric Paul Peck
NPI 1255347852
$6,755.27
in general payments reported to CMS, 2019-2025
44 companies · $695 in 2025
The $695 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,257 · 2020: $1,451 · 2021: $1,362 · 2022: $884 · 2023: $572 · 2024: $535 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $743.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $657.89 | 2019-2022 | |
| Abbvie INC. | $500.66 | 2020-2025 | |
| Pfizer INC. | $397.13 | 2019-2025 | |
| Amgen INC. | $384.43 | 2019-2025 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $358.54 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $355.01 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $338.66 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $288.96 | 2019-2025 | Vaxelis, Gardasil 9, Proquad |
| Glaxosmithkline, LLC. | $284.63 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.33 | 2019-2023 | Jardiance |
| Allergan, INC. | $250.49 | 2019-2020 | |
| Lilly USA, LLC | $230.96 | 2019-2025 | Jardiance, Mounjaro |
| Abbott Laboratories | $173.98 | 2019-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $169.25 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Peck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.